First-in-Human test of supercharged immune cells to fight advanced cancers
NCT ID NCT06942143
Summary
This is an early-stage safety study testing a new type of personalized cell therapy for patients with advanced solid tumors. Doctors will collect a patient's own immune cells, genetically modify them to better recognize a specific cancer marker called NY-ESO-1, and then infuse them back into the patient. The main goal is to find a safe dose and understand the side effects of this experimental treatment in a small group of up to 15 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Gaungdong, 510700, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.